Strategic assets EUROAPI operates five European API manufacturing sites and a broad portfolio of around 200 products, highlighting opportunities to propose supply chain resilience solutions, regional sourcing options, and co-development CDMO collaborations to reduce time to market for customers in Europe and beyond.

Public health focus The company emphasizes sustainable, high-quality API solutions and public health impact, presenting a sales angle for partners seeking compliant, reliable supply of essential actives, including collaborations on new drug development and access initiatives.

Transformation plan FOCUS-27 transformation and ongoing strategic option reviews for certain assets indicate potential for portfolio optimization partnerships, divestiture alternatives, or capacity reallocation discussions that could align with customers needing scalable manufacturing or site-specific capabilities.

Sustainability credibility Science-based targets and verified climate commitments strengthen EUROAPI’s positioning with ESG-conscious buyers; there is an opportunity to offer green chemistry programs, emissions reduction initiatives, and sustainability reporting services as value adds for customers.

Industry partnerships Recent collaborations and partnerships in microbial intermediate development and pharmaceutical innovation signals openness to co-development, technology transfer, and joint ventures that could expand product access, accelerate timelines, and broaden market reach for potential customers.